Addition of cisplatin improves efficacy of 131I-labeled monoclonal antibody 323A3 in experimental human ovarian cancer

This publication has 13 references indexed in Scilit:

• Comparison of the monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts
  British Journal of Cancer, 1996
• Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer
  European Journal Of Cancer, 1995
• SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2
  International Journal of Cancer, 1994
• Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody
  British Journal of Cancer, 1993
• Comparison of131I-labelled anti-episialin 139H2 with cisplatin, cyclophosphamide or external-beam radiation for anti-tumor efficacy in human ovarian cancer xenografts
  International Journal of Cancer, 1992
• Radiation and chemotherapy sensitizers and protectors
  Critical Reviews in Oncology/Hematology, 1990
• The effect of cisplatin on the repair of radiation damage in RIF 1 mouse tumours in vivo
  Radiotherapy and Oncology, 1989
• WiDr is a derivative of another colon adenocarcinoma cell line, HT-29
  Cancer Genetics and Cytogenetics, 1987
• Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data
  International Journal of Radiation Oncology*Biology*Physics, 1987
• The effect of treatment in fractionated schedules with the combination of x-irradiation and six cytotoxic drugs on the RIF-1 tumor and normal mouse skin
  International Journal of Radiation Oncology*Biology*Physics, 1985